vs
Side-by-side financial comparison of PARK AEROSPACE CORP (PKE) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $17.3M, roughly 1.6× PARK AEROSPACE CORP). PARK AEROSPACE CORP runs the higher net margin — 17.0% vs -147.1%, a 164.1% gap on every dollar of revenue. On growth, PARK AEROSPACE CORP posted the faster year-over-year revenue change (20.3% vs -67.6%).
Park Electrochemical Corp, now called the Park Aerospace Corp, is a Melville, New York-based materials manufacturer for the telecommunications, Internet infrastructure, high-end computing, and aerospace industries. It produces high-technology digital and radio frequency(RF)/microwave printed circuit material products, composite materials. Its printed circuit materials are used for complex multilayer printed circuit boards and other electronic interconnection systems, such as multilayer back-p...
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
PKE vs SPRY — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.3M | $28.1M |
| Net Profit | $3.0M | $-41.3M |
| Gross Margin | 34.1% | — |
| Operating Margin | 21.0% | -147.6% |
| Net Margin | 17.0% | -147.1% |
| Revenue YoY | 20.3% | -67.6% |
| Net Profit YoY | 87.1% | -182.8% |
| EPS (diluted) | $0.15 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.3M | $28.1M | ||
| Q3 25 | $16.4M | $32.5M | ||
| Q2 25 | $15.4M | $15.7M | ||
| Q1 25 | $16.9M | $8.0M | ||
| Q4 24 | $14.4M | $86.6M | ||
| Q3 24 | $16.7M | $2.1M | ||
| Q2 24 | $14.0M | $500.0K | ||
| Q1 24 | $16.3M | $0 |
| Q4 25 | $3.0M | $-41.3M | ||
| Q3 25 | $2.4M | $-51.2M | ||
| Q2 25 | $2.1M | $-44.9M | ||
| Q1 25 | $1.2M | $-33.9M | ||
| Q4 24 | $1.6M | $49.9M | ||
| Q3 24 | $2.1M | $-19.1M | ||
| Q2 24 | $993.0K | $-12.5M | ||
| Q1 24 | $2.7M | $-10.3M |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 31.2% | — | ||
| Q2 25 | 30.6% | — | ||
| Q1 25 | 29.3% | — | ||
| Q4 24 | 26.6% | — | ||
| Q3 24 | 28.5% | — | ||
| Q2 24 | 29.3% | — | ||
| Q1 24 | 27.3% | — |
| Q4 25 | 21.0% | -147.6% | ||
| Q3 25 | 17.4% | -163.7% | ||
| Q2 25 | 15.7% | -302.9% | ||
| Q1 25 | 16.8% | -466.3% | ||
| Q4 24 | 12.8% | 54.5% | ||
| Q3 24 | 15.7% | -1051.6% | ||
| Q2 24 | 14.9% | -3068.0% | ||
| Q1 24 | 15.7% | — |
| Q4 25 | 17.0% | -147.1% | ||
| Q3 25 | 14.7% | -157.4% | ||
| Q2 25 | 13.5% | -285.6% | ||
| Q1 25 | 7.4% | -425.7% | ||
| Q4 24 | 10.9% | 57.7% | ||
| Q3 24 | 12.4% | -925.0% | ||
| Q2 24 | 7.1% | -2503.2% | ||
| Q1 24 | 16.3% | — |
| Q4 25 | $0.15 | $-0.41 | ||
| Q3 25 | $0.12 | $-0.52 | ||
| Q2 25 | $0.10 | $-0.46 | ||
| Q1 25 | $0.06 | $-0.35 | ||
| Q4 24 | $0.08 | $0.52 | ||
| Q3 24 | $0.10 | $-0.20 | ||
| Q2 24 | $0.05 | $-0.13 | ||
| Q1 24 | $0.13 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.6M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $106.6M | $114.3M |
| Total Assets | $118.1M | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.6M | $245.0M | ||
| Q3 25 | $61.6M | $288.2M | ||
| Q2 25 | $65.6M | $240.1M | ||
| Q1 25 | $68.8M | $275.7M | ||
| Q4 24 | $70.0M | $314.0M | ||
| Q3 24 | $72.0M | $204.6M | ||
| Q2 24 | $74.4M | $218.7M | ||
| Q1 24 | $77.2M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $106.6M | $114.3M | ||
| Q3 25 | $105.8M | $147.7M | ||
| Q2 25 | $105.0M | $192.3M | ||
| Q1 25 | $107.2M | $229.0M | ||
| Q4 24 | $107.4M | $256.8M | ||
| Q3 24 | $110.3M | $201.0M | ||
| Q2 24 | $111.7M | $215.2M | ||
| Q1 24 | $112.9M | $223.9M |
| Q4 25 | $118.1M | $327.7M | ||
| Q3 25 | $116.4M | $372.8M | ||
| Q2 25 | $120.7M | $313.5M | ||
| Q1 25 | $122.1M | $327.3M | ||
| Q4 24 | $124.2M | $351.2M | ||
| Q3 24 | $125.1M | $217.6M | ||
| Q2 24 | $129.4M | $222.0M | ||
| Q1 24 | $132.3M | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.1M | $-43.5M |
| Free Cash FlowOCF − Capex | $4.3M | — |
| FCF MarginFCF / Revenue | 24.6% | — |
| Capex IntensityCapex / Revenue | 4.8% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.73× | — |
| TTM Free Cash FlowTrailing 4 quarters | $3.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $-43.5M | ||
| Q3 25 | $-2.1M | $-47.0M | ||
| Q2 25 | $1.6M | $-39.6M | ||
| Q1 25 | $969.0K | $-40.7M | ||
| Q4 24 | $2.7M | $42.0M | ||
| Q3 24 | $1.4M | $-14.5M | ||
| Q2 24 | $-423.0K | $-7.3M | ||
| Q1 24 | $5.3M | $-6.7M |
| Q4 25 | $4.3M | — | ||
| Q3 25 | $-2.3M | $-47.2M | ||
| Q2 25 | $1.1M | $-39.6M | ||
| Q1 25 | $338.0K | $-40.8M | ||
| Q4 24 | $2.7M | $41.7M | ||
| Q3 24 | $1.3M | $-14.6M | ||
| Q2 24 | $-435.0K | $-7.3M | ||
| Q1 24 | $5.1M | $-6.8M |
| Q4 25 | 24.6% | — | ||
| Q3 25 | -14.0% | -145.4% | ||
| Q2 25 | 7.2% | -252.2% | ||
| Q1 25 | 2.0% | -512.1% | ||
| Q4 24 | 18.6% | 48.2% | ||
| Q3 24 | 7.5% | -706.3% | ||
| Q2 24 | -3.1% | -1463.4% | ||
| Q1 24 | 31.4% | — |
| Q4 25 | 4.8% | 0.0% | ||
| Q3 25 | 1.1% | 0.6% | ||
| Q2 25 | 3.1% | 0.3% | ||
| Q1 25 | 3.7% | 1.1% | ||
| Q4 24 | 0.4% | 0.3% | ||
| Q3 24 | 1.2% | 6.8% | ||
| Q2 24 | 0.1% | 7.6% | ||
| Q1 24 | 1.0% | — |
| Q4 25 | 1.73× | — | ||
| Q3 25 | -0.88× | — | ||
| Q2 25 | 0.76× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 1.73× | 0.84× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | -0.43× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PKE
| North America | $16.8M | 97% |
| Other | $546.0K | 3% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
